Symptom control in advanced cancer.

Abstract:

:Most important is the physician's attitude, energy, and skill focused toward helping the patient through the difficulties in the last weeks of life. Many causes of nausea, dyspnea, and other troublesome symptoms can be effectively treated, and pharmacologic palliation is nearly always possible. A multidisciplinary team (ie, hospice) can help the physician see the whole picture and needs the physician's input to effectively manage physical, psychosocial, and spiritual components of the situation. The physician who attends to his own physical, psychosocial, and spiritual needs will have the stamina and depth of insight to help his patients through these difficult days. They can then complete their lives in the place of their choosing with the comfort and support needed to finish business, address strained relationships, and open to the mysteries of life and death.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Storey P

subject

Has Abstract

pub_date

1994-12-01 00:00:00

pages

748-53

issue

6

eissn

0093-7754

issn

1532-8708

journal_volume

21

pub_type

杂志文章,评审
  • Liver-directed therapies in colorectal cancer.

    abstract::The liver is the most common site of metastatic colorectal cancer (CRC) and the status of this organ is an important determinant of overall survival in patients with advanced disease. Complete resection of hepatic CRC metastases can provide a long-term cure for some patients, but the majority of liver metastases are n...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.025

    authors: Ruan DT,Warren RS

    更新日期:2005-02-01 00:00:00

  • Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies.

    abstract::Compelling data implicate angiogenesis and tumor-associated neovascularization as a central pathogenic step in the process of tumor growth, invasion, and metastasis. These complex processes involve multiple steps and pathways dependent on the local balance between positive and negative regulatory factors, as well as i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Pluda JM

    更新日期:1997-04-01 00:00:00

  • Vinorelbine (Navelbine) in the treatment of breast cancer: a summary.

    abstract::One of the new agents intensively studied in the last decade for the treatment of metastatic breast cancer is vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France). This vinca alkaloid produces response rates comparable to other single agents in women with m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Abeloff MD

    更新日期:1995-04-01 00:00:00

  • Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.

    abstract::The discovery of the HER2/neu proto-oncogene and its role in the pathogenesis of breast cancer tumors, and the development of the anti-HER2 monoclonal antibody, trastuzumab (Herceptin; Genentech, South San Francisco, CA), directed against the HER2 receptor represent major milestones in the research developments in bre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90188-5

    authors: Slamon D,Pegram M

    更新日期:2001-02-01 00:00:00

  • Overview of phase I trials of multitargeted antifolate (MTA, LY231514).

    abstract::Multitargeted antifolate (MTA, LY231514) is a novel antifolate antimetabolite, with antitumor activity via inhibition of thymidylate synthase, glycinamide formyl transferase, and dihydrofolate reductase. Three dosing schedules have been investigated in the phase I setting: daily x5 every 21 days, weekly x4 every 42 da...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rinaldi DA

    更新日期:1999-04-01 00:00:00

  • Is there a place for "dose-dense" weekly schedules of the taxoids?

    abstract::The recommended weekly dose and the maximum tolerated weekly dose of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) have yet to be determined. We report that a weekly dose of up to 40 mg/m2 docetaxel for 6 weeks is active in pretreated patients with metastatic breast cancer. From a preliminary study, this d...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Löffler TM

    更新日期:1998-10-01 00:00:00

  • Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.

    abstract::Data from various phase I/II studies of carboplatin in combination with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) have suggested that the degree of thrombocytopenia seen is less than that expected when carboplatin is given alone. However, some studies also have suggested that the area under the p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Calvert AH,Boddy A,Bailey NP,Siddiqui N,Humphreys A,Hughes A,Robson L,Gumbrell L,Thomas H,Chapman F

    更新日期:1995-10-01 00:00:00

  • Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.

    abstract::The side effects of cisplatin (75 mg/m2) in combination with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (175 mg/m2 over 3 hours) are expected to be more severe and frequent than those of carboplatin (area under the concentration-time curve of 5) in combination with the same dose of paclitaxel, but...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Neijt JP,Engelholm SA,Witteveen PO,Tuxen MK,Sørensen PG,Hansen M,Hirsch F,Sessa C,de Swart C,van Houwelingen HC,Lund B,Hansen SW

    更新日期:1997-10-01 00:00:00

  • Cellular immunotherapy and cancer.

    abstract::Recent data indicate that cellular immune responses can produce an anticancer effect. Two types of cellular immune responses appear to be clinically relevant: antigen specific immunity mediated by T cells that recognize tumor-associated peptide antigen expressed on surface HLA class I or class II molecules, and antige...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.02.021

    authors: Waller EK

    更新日期:2004-04-01 00:00:00

  • Radiation therapy in pregnancy: risk calculation and risk minimization.

    abstract::The benefits of radiation therapy (RT) as part of a treatment regimen for cancer must be weighed against the potential risk of harm to the patient and in the pregnant patient, the risk to the developing fetus. Information necessary for determining the potential effects of RT on the developing fetus include the gestati...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Greskovich JF Jr,Macklis RM

    更新日期:2000-12-01 00:00:00

  • Maintaining bone health in prostate cancer throughout the disease continuum.

    abstract::Prostate cancer (PC) is the most prevalent malignancy in men, with 604,506 new cases diagnosed yearly worldwide. Maintaining bone health is important during all stages of PC, including patients who experience bone loss from androgen-deprivation therapy and patients who develop bone metastases. Patients with bone metas...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.06.007

    authors: Saad F,Eastham J

    更新日期:2010-06-01 00:00:00

  • Screening diagnosis and staging of esophageal cancer.

    abstract::In geographic areas where there is a high risk of esophageal cancer, analysis of cells obtained from the esophagus has been used effectively to detect early lesions. This has been demonstrated on a large scale in studies from China. Using abrasive balloon cytology techniques, 75% of the cancers detected were early les...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Lightdale CJ,Winawer SJ

    更新日期:1984-06-01 00:00:00

  • Unusual variants of melanoma: fact or fiction?

    abstract::Evidence is reviewed separating unusual variants of melanoma from the large group of superficial spreading and nodular (SSM/NOD) histogenetic types. These include (1) the relationship of moles to melanoma of the SSM/ NOD types not found in melanoma arising in lentigo maligna (LMM), desmoplastic neurotrophic melanoma (...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Sagebiel RW

    更新日期:1996-12-01 00:00:00

  • Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group.

    abstract::Gemcitabine is an active agent in non-small cell lung cancer, with single-agent treatment producing response rates of approximately 20% and median survivals of approximately 7 to 9 months. In a pilot trial in advanced non-small cell lung cancer, the gemcitabine/carboplatin combination produced a response rate of 43% a...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1053/sonc.2002.34276

    authors: Sederholm C

    更新日期:2002-06-01 00:00:00

  • The treatment of painful osseous metastases with phosphorus-32-labeled phosphates.

    abstract::32P orthophosphate administered in a wide range of activity reduces or relieves the pain from osteoblastic metastases in approximately 80% of patients treated. The efficacy of this agent is equal to that of newer agents and of wide field radiotherapy, as documented in a literature review of 28 series reporting the use...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Silberstein EB

    更新日期:1993-06-01 00:00:00

  • The current status of toxicity protectants in cancer therapy.

    abstract::Current therapies for the treatment of malignancies are associated with significant toxicity, as chemotherapy and radiation therapy do not discriminate between normal and malignant cells. One approach to ameliorating the toxicity associated with therapy is through the use of chemoprotective agents. This article review...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schuchter LM,Luginbuhl WE,Meropol NJ

    更新日期:1992-12-01 00:00:00

  • The Veterans Precision Oncology Data Commons: Transforming VA data into a national resource for research in precision oncology.

    abstract::The Department of Veterans Affairs (VA) has a strong track record providing high-quality, evidence-based care to cancer patients. In order to accelerate discoveries that will further improve care for Veterans with cancer, the VA has partnered with the Center for Translational Data Science at the University of Chicago ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2019.09.002

    authors: Do N,Grossman R,Feldman T,Fillmore N,Elbers D,Tuck D,Dhond R,Selva L,Meng F,Fitzsimons M,Ajjarapu S,Ayandeh S,Hall R,Do S,Brophy M

    更新日期:2019-01-01 00:00:00

  • Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer.

    abstract::Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin production in pathologic states such as inflammatory processes and cancer. The enzyme is often overexpressed in premalignant lesions and various cancers, including cancer of the lung. Inhibition of this enzyme with selective COX-2 inhibitors was found to ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.12.014

    authors: Komaki R,Liao Z,Milas L

    更新日期:2004-02-01 00:00:00

  • Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.

    abstract::Gastrointestinal stromal tumor (GISTs) are the most common connective tissue malignancies of the gastrointestinal (GI) tract, with an incidence on the order of 10-13 per million people per year. Primary therapy is usually surgical, but the recurrence rate of large, so-called high-risk tumors, with a high mitotic rate,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.06.002

    authors: Reichardt P,Hogendoorn PC,Tamborini E,Loda M,Gronchi A,Poveda A,Schöffski P

    更新日期:2009-08-01 00:00:00

  • Cardiac testing to manage cardiovascular risk in cancer patients.

    abstract::Cardiovascular toxicity is one of the most feared complications of cancer treatment. Recent advances in oncologic therapies have resulted in improved cancer outcomes but also a new set of cardiovascular adverse effects. Common toxicities include left ventricular dysfunction/heart failure, hypertension, and myocardial ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.01.003

    authors: Davis M,Witteles RM

    更新日期:2013-04-01 00:00:00

  • Early studies of etoposide phosphate, a water-soluble prodrug.

    abstract::Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is converted in vivo by endogenous phosphatases to the active drug etoposide. This conversion process is efficient and not saturable in humans at doses between 50 and 1,600 mg/m2. The resultant eto...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Budman DR

    更新日期:1996-12-01 00:00:00

  • Epidemiology of acute myelogenous leukemia.

    abstract::The epidemiologic literature suggests that environmental exposures, familial susceptibility, and cytogenetic changes affect AML risk in childhood and adulthood. Unfortunately, many studies are limited by inadequate sample sizes, imprecise case definition, or inadequate exposure measurement. Few studies have singled ou...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sandler DP

    更新日期:1987-12-01 00:00:00

  • Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.

    abstract::Platinum compounds have long played a role in the treatment of gynecologic cancers. Single-agent cisplatin and carboplatin have shown activity in endometrial cancer, and more recent studies have begun to investigate a variety of new platinum-based combinations. In cervical cancer, chemotherapy is used primarily to tre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.11.007

    authors: Muggia FM

    更新日期:2004-12-01 00:00:00

  • Are sex discordant outcomes in COVID-19 related to sex hormones?

    abstract::COVID-19 has a clear sex disparity in clinical outcome. Globally, infection rates between men and women are similar; however, men are more likely to have more severe disease and are more likely to die. The causes for this disparity are currently under investigation and are most likely multifactorial. Sex hormones play...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2020.06.002

    authors: Strope JD,Chau CH,Figg WD

    更新日期:2020-10-01 00:00:00

  • Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma.

    abstract::Malignant biliary obstruction, duodenal, and gastric outlet obstruction, and tumor-related pain are the complications of unresectable pancreatic adenocarcinoma that most frequently require palliative intervention. Surgery involving biliary bypass with or without gastrojejunostomy was once the mainstay of treatment in ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.12.014

    authors: Stark A,Hines OJ

    更新日期:2015-02-01 00:00:00

  • Extending preclinical models of skeletal manifestations of malignancy to the clinical setting.

    abstract::There is a spectrum of presentations of skeletal manifestations of malignancy that includes generalized osteopenia and hypercalcemia, focal osteolysis, focal osteogenesis, and osteomalacia and hypophosphatemia. In various preclinical animal models, parathyroid hormone-related protein (PTHrP) was seen to be produced by...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90226-x

    authors: Goltzman D

    更新日期:2001-08-01 00:00:00

  • Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment.

    abstract::Long-term survival is occasionally observed in patients with neoplastic meningitis (NM) accompanying breast cancer (13% one-year and 6% 2-year survival), melanoma, and lymphoma, but in general the survival of most patients is short and averages only 3 to 4 months. The incidence of NM appears to be increasing, in part ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.04.016

    authors: Jaeckle KA

    更新日期:2006-06-01 00:00:00

  • Clinical trials with ifosfamide: the Indiana University experience.

    abstract::At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity--testicular cancer and smal...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Loehrer PJ,Williams SD,Nichols CR,Einhorn LH

    更新日期:1992-02-01 00:00:00

  • Antiestrogen therapy of breast cancer.

    abstract::Studies in vitro and in animal models have helped define the mechanism of action of antiestrogens and the differences in the physical properties of the various antiestrogens. Tamoxifen is the most widely studied antiestrogen. A review of 45 separate studies has shown a response rate to tamoxifen in advanced breast can...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lippman ME

    更新日期:1983-12-01 00:00:00

  • Non-small cell lung cancer treatment-related bone marrow toxicities.

    abstract::A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may al...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.03.014

    authors: Ettinger DS

    更新日期:2005-04-01 00:00:00